Antiviral Therapies

cocrystalpharma.com

Forward Looking Statements

This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created by third parties and the ability of clinical research organizations to recruit patients. Forward-looking statements also are prefaced by words such as "expect," "plan," "intend," "anticipate," and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including those contained in our Form 10-K, as amended, for the year ended December 31, 2015, form 10Q for the quarter ending June 30, 2016. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We do not undertake any duty to update these forward-looking statements.

2

cocrystalpharma.com

§ Clinicalstageantiviralcompany

§ Multipleopportunitiesindifferentviraldiseases

Company Highlights

3

Influenza PB2inhibitors,PA inhibitors,PB-1inhibitorsHepatitis C NNI,nucleosideinhibitors,helicaseinhibitors,NS5A

inhibitorsNorovirus Nucleoside inhibitors,NNIHepatitisB CRISPR/Cas 9Humanpapillomavirus CRISPR/Cas9

cocrystalpharma.com

Crystallography Technology Platform

§ Abilitytoquicklygrowultra-highresolutioncrystalsofreplicationenzymes

§ Rapidturnaround ofstructuralinformationthroughhighlyautomatedX-raydataprocessingandrefinement

§ Discoveryofnovelbindingsites –overlaystructureoffragmentsboundtonovelsites

§ Provides3Dstructureofinhibitorcomplexesatnear-atomicresolution–providesimmediateinsighttoguidedrugdiscovery

FragmentE

FragmentD

FragmentA

FragmentB

FragmentC

Fragmenthits

4

cocrystalpharma.com

Cocrystal Drug Discovery Process

Nearatomicresolution,X-rayqualitycrystalproduction

Drugpocketselection

Hit-to-leadprocess

Leadoptimization

Drugcandidates

5

cocrystalpharma.com

Opportunities

Thereexistssignificantunmetmedicalneedsacrossalargevarietyofviralinfectionsincluding…

HepatitisB&C

Leadingcausesofliverfailureandlivercancer

Chronicinfections>100millionHCV>400millionHBV

OpportunityforshorterdurationinHCVanda

cureinHBV

Norovirus

• Chronic(potentiallyorphanindication)

• Acutegastroenteritis

>250millionacutecases/year

NotreatmentavailableEconomiccostintheUS

alone >$5Billion

InfluenzaA&B

Seasonalandpandemic

3- 5millioninfections/year

EstimatedeconomicimpactofseasonalfluinUS:$50Bto$150B

6

cocrystalpharma.com

Company Pipeline

7

Therapeutic area LeadDiscovery

Preclinical Phase I PhaseII

HepatitisCCC-31244(NNI)

Hepatitis CCC-2069(NS5A)

HepatitisCCC-2850 (Nuc)

Influenza APB2inhibitor

NorovirusNuc&NNI

HepatitisBandHPV(CRISPR/Cas9)

cocrystalpharma.com

HCV Market Dynamics

8

Today and in the future

*BloombergIntelligence(BI)projections,asof2016

§ Hugemarket:>10millionpatientsacrosstheUS,Japan,WesternEurope

§ Currentlytreating400,000+patientsperyear

§ Manyundiagnosedpatients

§ Pricingwillbecompetitive,butthemarketwillstillbesignificantintheforeseeablefuture

§ Greatneedforashorterdurationtherapy

cocrystalpharma.com

Cocrystal’s HCV DAA Combinations

Multipleopportunitiesindevelopingcombinationultra-short,alloralpan-genotypiccure(in-houseorwithpartners)

Pan-genotypicNS5BNuc

Pan-genotypicNS5AInhibitor

Pan-genotypicNS5BNNI

9

Oral,Pan-genotypic,Ultra-shorttherapy

cocrystalpharma.com

CC-31244: Pan-genotypic NNI

10

§ HighlypotentNS5Bpolymeraseinhibitor(EC50=7nM)

§ Pan-genotypicactivity(genotypes1-6)

§ Highbarriertodrugresistance

§ PhaseIa doseescalatingsafetystudycompleted

§ ViralloaddatainHCVsubjectsavailableinQ4,2016

cocrystalpharma.com11

0

200

400

600

800

1000

1200

1400

1600

1800

1 2 3 4 5

IC50foldch

ange

HCV-796

31228 CC-31244 959 985 HCV-796

Cocrystal’sNNI-4Leads

Cocrystal’sBackupLeads

S365T(NNI-4)

N316Y(NNI-4)

L419M(NNI-2)

S282T(Nuc)

Drugresistancevariants

Unique Drug Resistance Property of Cocrystal NNIs

§ CC-31244showspan-genotypicandbroadactivityagainstcommondrugresistantvariants

11

cocrystalpharma.com

CC-31244 Phase Ia Clinical Trial Update

12

§ Asingle- andmultiple-doseassessmentofthesafetyandpharmacokineticsofpan-genotypicNNI,CC-31244

• Single-dosecompleted:fivecohortsofhealthyvolunteersat10,50,100,200,and400mg

• Multiple-dosecompleted:twocohortsofhealthyvolunteersat200mgx7daysand400mgx7days)

• Noadverseeffectsobserved

cocrystalpharma.com

CC-31244 Phase Ib Clinical Trial Update

13

§ Proof-of-conceptPhase1bstudyongoing

• HCVinfectedsubjectswithminimalfibrosisandnosignificantco-morbidities

• Repeat-dose,randomized,monotherapytrial(400mgx7days)

• Viralload,drugresistance,andpharmacokineticpropertieswillbedetermined

cocrystalpharma.com

CC-2069: Pan-genotypic NS5A

§ Novel,highlypotent,pan-genotypic,NS5Ainhibitor(GT1bEC50<10pM)

§ ActiveagainstcommonNS5Adrugresistantvariants

§ Preclinicalcharacterizationongoing

14

cocrystalpharma.com

HCV Nucleoside Program: CC-2850

Searchfornextgenerationbackboneforcombinationtherapy

15

§ Novel,potent,pan-genotypic nucleosideinhibitor

§ Activeagainstcommonnucleosideinhibitordrugresistant(S282T)

§ Preclinicalcharacterizationongoing

cocrystalpharma.com

HCV Helicase Lead Discovery Program

Providesuniqueopportunitiesfordrugcombinations

§ InhibitsessentialviralRNAunwindingprocess

§ First-in-classpan-genotypicinhibitors(newmechanismofaction)

§ Highlyconserveddrugbindingmodedemonstratedinallgenotypecrystalsdeveloped(Genotypes1-6)

§ PotentiallyanidealcombinationcandidatewithHCVNuc,NNI,NS5A,and/orproteaseinhibitors

16

cocrystalpharma.com

Influenza Program

Influenzaleads:PB2,PB1andPAInhibitors

§ Focusonthreedifferenttypesofinfluenzapolymeraseinhibitors:PB2(cap-binding),PB1(polymerase),andPA(endonuclease)

§ Novel,potentstructure-basedinfluenzaAPB2inhibitorsareatpreclinicalstage

17

cocrystalpharma.com

Influenza Program

PotentPB2leadsbindtohighlyconservedbindingpocket

H1N12009

Virginia

H1N11918

Spanish

H7N92013

Zhejiang

H5N11996

Guangdong • H1N1 1918

• H1N1 2009• H5N1 1996 • H7N9 2013

InfluenzaPB2inhibitorSelectedinfluenzaAPB2crystals

18

cocrystalpharma.com

Norovirus Program

Unmet&underappreciatedmedicalneed

§ Prophylaxis

§ TreatmentØ Acute(foodborne)

Ø Chronic(Immunocompromised)

Ø Chronic(transplantpatients)

19-20millionillnesseachyear(1in14Americansbecomeilleachyear)

19

cocrystalpharma.com

Norovirus Program

BroadspectrumNoro PolymeraseInhibitors

• HumanNorwalk• HumanNoro• MurineNoro

Noronucleosides NoroNNI

HumanNoro HumanNorwalk MurineNoro

20

§ Drugable pocketidentified§ Activenucleosidecandidatesidentified

§ Animalmodeldatasupportsactivityinvivo

§ Leaddiscoveryisongoing

cocrystalpharma.com

Hepatitis B Market

21

§Hugemarket:400millionchronicallyinfectedglobally;asmanyas2millioninfectedwithchronicHBVinUSalone

§ Currenttherapiesonlysuppress,butdonoteliminate

There is no approved cure at this time

cocrystalpharma.com

CRISPR/Cas9 For Potential HBV Therapy

22

§ In-licensedfromDukeUniversityandEmoryUniversityforHepatitisBandHumanPapillomaVirus

§ CRISPR/Cas9allowsforeditingofviralDNA

§ PotentialcureforchronicHBV

cocrystalpharma.com

Cocrystal Board of Directors

RaymondSchinazi(Chairman)

GaryWilcox(ViceChairman)

DavidBlock

PhilFrost

JaneHsaio

StevenRubin

23

cocrystalpharma.com

Cocrystal Management

24

GaryWilcox,Ph.D.,InterimCEOChairmanandCEOofCocrystalPharma2008-2014;BoardofDirectorsandExecutiveVicePresidentofOperationsofIcosCorporation(ICOS-NASDAQ)from1993to2007.ViceChairman,ExecutiveVicePresident,andDirectorofXomaCorporation(XOMA-NASDAQ);Chairman,CEO,andPresidentofIngene(IGEI-NASDAQ)from1982-1989;ProfessorofMicrobiologyatUCLAfor10years.

SamLee,Ph.D.PresidentPresidentofCocrystalPharma2008-present;Anti-infectivedrugdiscoveryprojectmanagementICOSCorporation1999-2008.Dr.LeereceivedhisPh.D.inBiologicalSciencesfromtheUniversityofNotreDameandpostdoctoraltraininginviralbiochemistrywithDr.I.R.LehmanatStanfordUniversity.

CurtisDale,InterimChiefFinancialOfficerandControllerCorporateControllerSolvayPharmaceuticals;ExecutiveFinanceDirector,Stiefel Laboratories;Multiplefinancialpositions,Bristol-MeyersSquibb.

WaltLinscott,GeneralCounselandCorporateSecretaryGeneralCounselandCorporateSecretary,Carestream Health;VicePresident,GeneralCounselandCorporateSecretary,SolvayPharmaceuticals;ChairofLifeSciencesPracticeofaninternationallawfirm.

cocrystalpharma.com

Scientific Leadership

Dr.RaymondSchinaziCo-FounderofPharmasset,Idenix,Triangle;Founder,RFSPharma

Dr.RogerKornbergCocrystalCo-founder2006Nobelprizewinnerinchemistry

25

cocrystalpharma.com

Transformational Year: 2016

HCV§ InitiatedclinicaltrialforCC-31244(NNI)§ CompletedPhaseIa doseescalationsafetystudy§ AntiviralactivitydatainHCVsubjectsforCC-31244inQ42016§ PreclinicalcharacterizationofCC-2069(NS5A)- ongoing§ PreclinicalcharacterizationofCC-2850(Nuc)- ongoing

Influenza§ LeadselectionofinfluenzaAPB-2inhibitors

Norovirus§ Nucleoside/NNIindiscoverystage

HBV(CRISPRCas 9)§ InvitroproofofconceptandanimalmodelstudiesofCRISPR/Cas9

forhepatitisB– ongoing

26